Biotech 2008 - Panelists

Edgar Adams, ScD, executive director, epidemiology, Covance Inc.
Elizabeth Anderson, worldwide vice president for immunology and respiratory, global strategic marketing, Johnson & Johnson
Simon Archibald, Ph.D., CSO, Integra LifeSciences Corporation
Jane Baj, associate director of public and investor relations, PTC Therapeutics, Inc.
Stephanie Baldwin, senior manager, investor relations and corporate communications, Antares Pharma Inc.
Michael Becker, president & CEO, VioQuest Pharmaceuticals, Inc.
David Bergstrom, Ph.D., senior vice president & COO, NovaDel Pharma, Inc.
Mel Billingsley, Ph.D., president & CEO, Life Sciences Greenhouse of Central Pennsylvania
Jeffrey Bockman, Ph.D, vice president, Defined Health
Michael Bozik, M.D., president and CEO, Knopp Neurosciences, Inc.
Mary Del Brady, president & CEO, RedPath Integrated Pathology
Todd Brady, M.D., Ph.D., principal, Domain Associates, Inc.
Maurice Briggs, Ph.D., former senior director, regulatory affairs, Genmab, Inc.
Arthur Caplan, Ph.D., chair, department of medical ethics, University of Pennsylvania
Chris Cashman, president & CEO, Protez Pharmaceuticals
John Crowley, president and CEO, Amicus Therapeutics
Barbara Dalton, vice president, Pfizer Venture Capital
Manya Deehr, chief legal officer, Eurand
Jim Dentzer, CFO, Amicus Therapeutics
Barbara Deptula, executive vice president, business development, Shire Pharmaceuticals
John Elicker, vice president, investor relations, Bristol-Myers Squibb Company
Mike Erickson, Ph.D., associate partner, McKinsey & Company
David Fischell, Ph.D., CEO, Angel Medical Systems, Inc.
Jamie Freedman, M.D., Ph.D., president, CEO and director, Locus Pharmaceuticals, Inc.
William Foster, senior director, global hematology & oncology, communication and public affairs, Ortho Biotech, Inc.
Russ Gantt, vice president, corporate development, North America, AstraZeneca
Brian Gill, vice president, global corporate communications, Celgene Corporation
James Gilligan, Ph.D., MSIB, vice president for product development, Unigene Laboratories, Inc.
Glenn Gormley, M.D., Ph.D., president and CEO, Gemin X Pharmaceuticals, Inc.
Troy Harmon, vice president, business development, Eurand
Robert Hayes, Ph.D., venture leader, Centyrex, Johnson & Johnson Ventures
Janice Hogan, managing partner, Hogan & Hartson LLP
Tamar Howson, corporate and business development
Robert Hrubiec, Ph.D., J.D., vice president, intellectual property, Cephalon, Inc.
Dennis Jackman, senior vice president, public affairs, CSL Behring
John Johnson, CEO, ImClone Systems Incorporated
Perry Karsen, senior vice president, business development, Celgene Corporation
Richard Kender, senior vice president, business development & corporate licensing, Merck & Co., Inc.
Joachim Kohn, Ph.D., professor of Chemistry & Chemical Biology, Rutgers, the State University of New Jersey
Ray Krauss, CEO, GlucoLight Corporation
Barry Kreiswirth, Ph.D. director, PHRI TB Center, University of Medicine and Dentistry of New Jersey
Karen LaRochelle, executive director, business development, Bristol-Myers Squibb Company
Frank LaSaracina, managing director, Speedel Pharmaceuticals, Inc.
Len Lavenda, vice president, communications, sanofi pasteur US
King Lee, Ph.D., R.A.C., vice president, regulatory and clinical affairs, Cornerstone Pharmaceuticals, Inc.
Greg Licholai, M.D., vice president, medical affairs, Amicus Therapeutics
Laura Liotta, president, Sam Brown
Nils Lonberg, Ph.D., senior vice president & scientific director, Medarex, Inc.
Doug Long, vice president of industry relations, IMS HEALTH
Julia Lukas, director, regulatory affairs compliance, sanofi pasteur
Annarie Lyles, Ph.D., senior vice president, head of business development, Genmab, Inc.
John Maki, president & CEO, Vicus Therapeutics
Jeffrey Marx, Ph.D., vice president of corporate development, Orthovita, Inc.
Paul Medeiros, principal, The BioTransactions Group
Ross Murdoch, senior vice president, emerging business unit, Shire Pharmaceuticals
Brian Murphy, partner, NewSpring Capital
P. Sherrill Neff, managing partner, Quaker BioVentures
Steven Nichtberger, M.D., president & CEO, Tengion Inc.
Nicholas Nicolaides, Ph.D., president & CEO, Morphotek, Inc.
Shawn Patrick O'Brien, president & CEO, Profectus BioSciences Inc.
Tom Petzinger, CEO, LaunchCyte LLC
Peter Pfreudschuh, CFO, CircuLite
David Pompliano, Ph.D., vice president and head of antimicrobials discovery and early development strategy, Merck Research Laboratories
Tibby Posillico, Ph.D., president & CEO, Elusys Therapeutics, Inc.
Steven Projan, Ph.D., vice president and global head of infectious diseases, Novartis Institutes for BioMedical Research
Navaneetha Rao, Sc.D., vice president clinical research and development, Vicus Therapeutics
H. Joseph Reiser, Ph.D., president & CEO, CureDM Inc.
William Roberts, vice president of corporate communications, ViroPharma Incorporated
Charles Rowland, Jr., vice president & CFO, ViroPharma Incorporated
Avijit Roy, Ph.D, director, Five Prime Advisors
Will Sargent, vice president of investor relations & corporate communications, Auxilium Pharmaceuticals, Inc.
Glenn Sblendorio, CFO & executive vice president, The Medicines Company
Christian Schade, senior vice president, finance & administration and CFO, Medarex, Inc.
Zev Scherl, general partner, NewSpring Capital
Barbara Schilberg, managing director & CEO, BioAdvance
Chris Schnittker, CPA, vice president & CFO, VioQuest Pharmaceuticals, Inc.
Gary Sender, CFO and vice president of finance & administration, Tengion Inc.
Scott Siegel, Ph.D., vice president of corporate development, RedPoint Bio Corporation
Philip Smith, partner, SR One
Mel Sorensen, M.D., president and CEO, Ascenta Therapeutics, Inc.
Jack Stover, former CEO, Antares Pharma Inc.
Chris Szustkiewicz, Ph.D., MBA, vice president of regulatory affairs & compliance, Lux Biosciences
Kevin Taylor, vice president, business development, Adolor Corporation
Paul Thomas, former chairman, president & CEO, LifeCell Corporation
Steve Tullman, president & CEO, Ception Therapeutics, Inc.
Anne VanLent, president, AMV Advisors
Bruce Wagman, RN, MBA, RAC, vice president, regulatory affairs and quality assurance, clinical development services, Covance Inc.
Tim Wert, senior director, provider & payor services, ImClone Systems Incorporated
Michael Williams, Ph.D., D.Sc., vice president, discovery research, Cephalon, Inc.
Zhenping Zhu, M.D., Ph.D., vice president of research, ImClone Systems Incorporated

Edgar Adams, ScD, executive director, epidemiology, Covance Inc.

At Covance, Edgar Adams, ScD provides scientific and technical leadership in epidemiology, biometrics, and risk management. Having more than 15 years experience designing and implementing RiskMAPs, he was a commissioned officer in the US Public Health Service and served as chief epidemiologist at the National Institute on Drug Abuse, receiving a Surgeon General's commendation for contributions to epidemiology. He has a B.S. in Pharmacy (Fordham), an M.S. in Pharmacology (Purdue) and an Sc.D. (Johns Hopkins School of Public Health).

Elizabeth Anderson, worldwide vice president for immunology and respiratory, global strategic marketing, Johnson & Johnson

Liz Anderson is the worldwide vice president for Immunology and Respiratory, Global Strategic Marketing at Johnson & Johnson, where she and her team are responsible for the commercial development of a robust NME pipeline, including the global launch compounds Ustekinumab and Golimumab. With more than 25 years of biopharmaceutical business, Ms. Anderson joined Centocor, Inc. in 2003 and has led strategic marketing organizations since 2004, with responsibility for the biotech pipeline. Previously, she served as the vice president and general manager of Wyeth Lederle Vaccines and as the vice president & general manager for the NA biopharmaceuticals business of RPR. Ms. Anderson is a Tau Beta Pi graduate of Rutgers College of Engineering and holds an MBA in Finance from the Sellinger School, Loyola College.

Simon Archibald, Ph.D., CSO, Integra LifeSciences Corporation

Simon Archibald, Ph.D., is chief scientific officer for Integra LifeSciences Corporation. He joined Integra in 1997 to commercialize the NeuraGen nerve guide system. In 1997 he initiated the development of the DuraGen dural graft matrix for which he is a co-inventor. Previously he was an assistant professor in the Department of Neurosurgery at Duke University Medical Center and did his research fellowship in the Department of Neuropathology and Neuroscience, Harvard. He graduated with a degree in Zoology from the University of Reading, UK, and has a Ph.D. in Biomedical Engineering from the University of North Staffordshire, UK.

Jane Baj, associate director of public and investor relations, PTC Therapeutics, Inc.

Jane Baj joined PTC in February 2004. As associate director, public and investor relations at PTC Therapeutics, she is responsible for the implementation of the overall public relations strategy, including corporate communications and media and investor relations activities. Prior to joining PTC, Ms. Baj worked at Mojave Therapeutics, Inc, a biotechnology company focused on vaccine development, most recently as an associate director of corporate affairs. During the five years she spent at Mojave, Ms. Baj played a key role in establishing the company's public image in addition to creating internal and external corporate communication structures.

Stephanie Baldwin, senior manager, investor relations and corporate communications, Antares Pharma Inc.

Ms. Baldwin is senior manager of investor relations and corporate communications for Antares Pharma, Inc., where she created and implemented the formal strategic investor relations program resulting in new sell-side analyst coverage (four) and new institutional investors ($50M+). Previously, she managed the communications programs for private companies as well as governmental body (judicial). Ms. Baldwin serves as vice president on the Board of the National Investor Relations Institute (NIRI), Philadelphia Chapter and is a Charter Member of the NIRI BioPharma Roundtable. She currently serves as a Biotech 2008 communications committee co-chair for BioNJ.

Michael Becker, president & CEO, VioQuest Pharmaceuticals, Inc.

Michael Becker joined VioQuest Pharmaceuticals as president and CEO in November 2007. Previously, he served as president and CEO of Cytogen Corporation since December 2002. He joined Cytogen in April 2001 and held positions of increasing responsibility. During his tenure at Cytogen, Mr. Becker raised in excess of $130 million in new capital. Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based brokerage from July 1996 to April 2001. He founded and was executive editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker attended DePaul University. He is chairman of BioNJ.

David Bergstrom, Ph.D., senior vice president & CEO, NovaDel Pharma, Inc.

Dr. David Bergstrom joined NovaDel in December 2006 as senior vice president and CEO. From 1999 to November 2006, he held several positions at Cardinal Health, Inc., including vice president of R&D, SVP and GM. From 1998 to 1999, he was vice president of pharmaceutical & chemical development at Guilford Pharmaceuticals Inc. He worked for Hoechst Marion Roussel, Inc. and its predecessor company, Hoechst-Roussel Pharmaceuticals from 1991 to 1998 and has also held various positions at Ciba-Geigy Corporation. He received his Ph.D. in Pharmaceutics at the University of Utah in 1985, MS in Pharmaceutical Chemistry at the University of Michigan in 1982 and BS in Pharmacy in 1978 at Ferris State University.

Mel Billingsley, Ph.D., president & CEO, Life Sciences Greenhouse of Central Pennsylvania

Mel Billingsley, Ph.D., is president and CEO of the Life Sciences Greenhouse, professor of Pharmacology at Pennsylvania State University Milton S. Hershey College of Medicine, and professor of Biotechnology and Entrepreneurship, Penn State (Harrisburg). His background includes experience as a well-published researcher, educator, and as an investor; he has a long history of fostering the advancement and development of biotechnology. Dr. Billingsley leads the LSGPA participation in Gap and Tech Fund investments. He has an undergraduate degree in Biophysics and Microbiology from the University of Pittsburgh, a doctoral degree in Pharmacology from George Washington University, and a postdoctoral degree in neuropharmacology from Yale School of Medicine.

Jeffrey Bockman, Ph.D, vice president, Defined Health

Jeffrey Bockman, Ph.D., is vice president at Defined Health where he leads commercial and strategic assessments in oncology, inflammation and viral diseases. He was a senior scientist and project leader in oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories. He was also an assistant research professor at The George Washington University School of Medicine before this, where he continued from his original Ph.D. work on prions with Dr. David Kingsbury and Dr. Stanley Prusiner. He is a member of the Licensing Executives Society. He received a BA from UC San Diego, a Ph.D. in Medical Microbiology from UC Berkeley, and an MA in English/Creative Writing from NYU.

Michael Bozik, M.D., president and CEO, Knopp Neurosciences, Inc.

Dr. Bozik is president and CEO of Knopp Neurosciences, Inc. Prior to joining Knopp, he served as a global vice president of research and development for Bayer Healthcare and as vice president of research, development, and business operations for Bristol-Myers Squibb's worldwide consumer medicines division. He previously co-directed the University of Pittsburgh Cancer Institute's Brain Tumor Center and served as chief of the Division of Neuro-Oncology. He received his BA from the University of Notre Dame, his M.D. from the University of Pittsburgh and conducted his post-graduate training at the University of Michigan and the University of Pittsburgh.

Mary Del Brady, president & CEO, RedPath Integrated Pathology

Mary Del Brady is currently president and CEO of RedPath Integrated Pathology, Inc., one of the first commercial laboratories to integrate genomic analysis with everyday clinical care and the sole provider of PathFinderTG®, personalized molecular analysis that helps pathologists and oncologists to resolve diagnostic and treatment dilemmas for their patients. Prior to RedPath, she was co-founder and president of TissueInformatics.Inc (TII), one of Pittsburgh's first and highly regarded biotechnology companies. A small business owner and advocate who launched her first start-up at the age of 24, Ms. Brady has also served in numerous leadership capacities, has been the recipient of numerous awards including the E & Y Entrepreneur of the Year award and the University of Pittsburgh's Katz Graduate School of Business Distinguished Alumnus Award.

Todd Brady, M.D., Ph.D., principal, Domain Associates, LLC

Dr. Todd Brady joined Domain Associates in 2004. Present board memberships include Asmacure, Evoke Pharma, Neuron Systems, Novadigm Therapeutics, ParinGenix, and Symphony Medical with observer status at Carticept Medical, Celator Pharmaceuticals, Esperion Therapeutics, Helixis, Meritage Pharma, Microchip Biosciences, Orqis Medical, and Cortria Corporation. He is also on the New Jersey Commission on Science and Technology's grant review board, the VC advisor to BioNJ, a board member of the Southeast BIO, and advises Wake Forest University's Translational Science Institute. Before Domain, he was co-founder and CEO of Phenome Sciences, which he merged with Xanthus Pharmaceuticals. A graduate of Dartmouth College, he received M.D. and Ph.D. degrees from Duke University.

Maurice Briggs, Ph.D., former senior director, regulatory affairs, Genmab, Inc.

Maurice Briggs, Ph.D., has more than 20 years of research and development experience in the biotechnology and pharmaceutical industries. He joined Genmab as senior director, regulatory affairs in 2008 from AstraZeneca Pharmaceuticals, where he was director of regulatory affairs. He earned his BS degree in biology from the University of Texas and a Ph.D. from University of Oklahoma Medical Branch in Pharmacology. He also completed a Research Fellowship at Harvard Medical School, Beth Israel Hospital.

Arthur Caplan, Ph.D., chair, department of medical ethics, University of Pennsylvania

Dr. Caplan is currently the Emmanuel and Robert Hart professor of Bioethics, chair of the Department of Medical Ethics and the director of the Center for Bioethics at the University of Pennsylvania in Philadelphia. He is also the author or editor of 29 books, including his most recent, Smart Mice Not So Smart People (Rowman Littlefield, 2006), and more than 500 papers in refereed journals. Dr. Caplan is a member of the board of directors of The Keystone Center, Tengion, the National Center for Policy Research on Women and Families, Octagon, Iron Disorders Foundation, the National Disease Research Interchange, and is also on the Board of Visitors of the Columbia University School of Nursing. He writes a regular column on bioethics for MSNBC.com and is a frequent guest and commentator on various media outlets. Dr. Caplan did his undergraduate work at Brandeis University, and did his graduate work at Columbia University where he received a Ph.D. in the history and philosophy of science.

Chris Cashman, president & CEO, Protez Pharmaceuticals

Mr. Cashman is a co-founder of Protez Pharmaceuticals, Inc. and serves as director, president and CEO. He has 28 years experience in the pharmaceutical industry with a wide range of roles from president and CEO, Message Pharmaceuticals, global director new product development at Pfizer and vice president sales and marketing positions for both Pfizer and SmithKline Beecham. Mr. Cashman began his career at SmithKline Corporation serving in a variety of roles in marketing, sales, and management. He holds an M.S. in Economics from Purdue University and B.S. Business Management from the University of Minnesota. He recently concluded a merger of Protez with Novartis in July 2008.

John Crowley, president and CEO, Amicus Therapeutics

John Crowley is president and CEO of Amicus Therapeutics. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, he was senior vice president at Genzyme Therapeutics and held several senior management roles with the Bristol-Myers Squibb. Mr. Crowley began his career as a litigation associate in the Health Care Practice Group of Bingham, Summers, Welsh & Spilman. Mr. Crowley is a commissioned officer in the United States Navy Reserve (active). He earned his B.S. degree from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.

Barbara Dalton, vice president, Pfizer Venture Capital

Barbara Dalton is a pharmaceutical executive who has spent more than 20 years in the industry - most of that time as a corporate venture capitalist. She was trained as a research scientist at The Medical College of Pennsylvania and pursued drug discovery research at SmithKline prior to joining their venture capital group, S.R. One, Limited. Ms. Dalton was a founding member of EuclidSR Partners, a private New York based venture capital firm where SmithKline (now GSK) was a leading limited partner. She joined Pfizer in 2007 to grow their corporate venture activities. She has managed investments in funds and many diverse healthcare and life science companies in the US and Europe. She routinely represents her firm's investments by participating at the board level. She is an advisor to the Dean of the Eberly College of Science at Penn State, where she received her undergraduate degree. She serves on the board of The Penn State Research Foundation Board, New York Biotech Association and the National Venture Capital Association.

Manya Deehr, chief legal officer, Eurand

Manya Deehr is chief legal officer and general counsel for Eurand. Prior to joining Eurand, she was a partner at Morgan, Lewis & Bockius, LLP. Her practice over the last 17 years has been exclusively focused on the special business and legal needs of public and private life sciences companies. Ms. Deehr has represented and advised emerging growth companies as well as pharmaceutical companies in structuring and negotiating some of the largest pharmaceutical ventures ever completed. She employs her technical experience as a patent attorney in the context of business transactions.

Ms. Deehr earned an A.B. in biochemistry from Harvard University and her law degree from the University of Wisconsin Law School. She is currently admitted to practice in Colorado, Pennsylvania and California and before the U.S. Supreme Court, the U.S. Patent and Trademark Office and the U.S. Court of Appeals for the Federal Circuit.

Jim Dentzer, CFO, Amicus Therapeutics

Jim Dentzer joined Amicus in September 2006 as CFO. He joined the company from Biogen Idec Inc. where he served as corporate controller from November 2003 to September 2006. Prior to the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation, Mr. Dentzer served as corporate controller of Biogen, Inc. Prior to Biogen, he served in a variety of financial positions at E. I. du Pont de Nemours and Company, most recently as CFO of DuPont Flooring Systems. Mr. Dentzer received a B.A. from Boston College and an M.B.A. from the University of Chicago.

Barbara Deptula, executive vice president, business development, Shire Pharmaceuticals

Barbara Deptula joined Shire Pharmaceuticals in 2004 to lead the strategic refocus of the company's pipeline through merger and acquisition and product in-license. In her 20 plus year career in the pharmaceutical industry, Ms. Deptula has a broad experience base spanning from merger and acquisition to sales and marketing, new product development, international and general management.

Prior to joining Shire, she has held executive positions at Sicor Pharmaceuticals, Coley Pharmaceuticals, US Bioscience and Schering-Plough. In 2007, Ms. Deptula was named one of "Pennsylvania's 50 Best Women in Business." A graduate of the University of Chicago Business School with an MBA, she also holds a BS in pharmacy from the University of Connecticut.

John Elicker, vice president, investor relations, Bristol-Myers Squibb Company

John Elicker joined Bristol-Myers in 2000 as senior director, investor relations with primary responsibility for interacting with the professional investment community. In 2002, he was promoted to his current position of vice president, investor relations as the company's primary contact with the institutional investment community. Prior to joining the company, he was director, sales and development at Grainger.com with responsibility for leading the development and implementation of the National Sales and Business Development strategy for the company. From 1984 to 1994, Mr. Elicker was with Scott Paper Company advancing through positions of increasing responsibility in sales and marketing. He was marketing director, commercial business from 1992-1994. Mr. Elicker earned a Bachelor of Science degree from Pennsylvania State University and holds a Masters of Business Administration degree from The Wharton School at the University of Pennsylvania.

Mike Erickson, Ph.D., associate partner, McKinsey & Company

Mike Erickson is an associate partner in McKinsey & Company's New Jersey Office. Since joining the Firm, he has focused on serving pharmaceutical, biotechnology and medical device clients, primarily on commercial and corporate strategic issues. He is a leader of McKinsey's Specialty Care Commercial Excellence practice group and is a member of the Pharmaceutical / Medical Products leadership team. Dr. Erickson has a Ph.D. in Biomedical Engineering from the Johns Hopkins School of Medicine and a B.S. in Electrical Engineering from Purdue University.

David Fischell, Ph.D., CEO, Angel Medical Systems, Inc.

David Fischell, Ph.D., a serial entrepreneur, has founded nine biomedical device companies in 20 years, including Angel Medical Systems, Neuralieve, Inc. and NeuroPace, Inc. Dr. Fischell joined Bell Laboratories following his Ph.D. from Cornell, in 1979 where, for 11 years, he performed and directed a wide range of R&D projects. He left in 1991 to work full time on medical devices. He currently holds 89 issued US patents and is a director of seven biomedical technology companies. He was also the primary designer of the "BX Velocity" and "Cypher" coronary stents for Cordis/J&J. He is a trustee of Cornell University.

Jamie Freedman, M.D., Ph.D., president, CEO and director, Locus Pharmaceuticals, Inc.

Jamie Freedman, president and CEO of Locus Pharmaceuticals, joined Locus as chief medical officer in January 2008. Previously, Dr. Freedman was at Merck Research Labs holding positions of increasing responsibility in clinical research. During this period, he oversaw several drug development programs, and also supervised a group qualifying biomarkers in clinical trials and developing new clinical models for proof-of-concept. Dr. Freedman received M.D. and Ph.D. degrees from Tufts University, and trained in medicine and hematology-oncology at UCSF and Harvard, respectively. He also held a staff position in the Department of Medicine at the University of Pennsylvania.

William Foster, senior director, global hematology & oncology, communication and public affairs, Ortho Biotech, Inc.

William Foster is a communications leader with 20 years of experience, primarily in the healthcare arena. Currently, he leads organizational communications and global communications for the hematology and oncology products of Ortho Biotech, Inc. Prior to joining Ortho Biotech, he assumed roles of increasing responsibility at other Johnson & Johnson operating companies and at Burson-Marsteller, a global public relations agency based in New York.

Russ Gantt, vice president, corporate development, North America, AstraZeneca

Mr. Gantt is vice president, corporate development, North America for AstraZeneca where he heads up the US hub and is a member of the Global Leadership Team. Mr. Gantt and his US based Strategic Planning and Business Development Team are responsible for the management of various types of transactions including licenses, acquisitions, divestments and alliances both for the US and Global Pharmaceutical business of AZN. During his career, he has held various positions with Abbott, Schering-Plough, Wyeth, Astra-Merck and now with AstraZeneca. He is currently based in AstraZeneca's North American headquarters in Wilmington, Delaware.

Brian Gill, vice president, global corporate communications, Celgene Corporation

Brian Gill has been responsible for corporate communications at Celgene since 2003. Prior to joining Celgene, he served for more than eight years as managing director for communication firms in New York City creating global communications programs for healthcare and biotech companies. Prior to that, Mr. Gill held director and management positions, both domestic and internationally, with leading healthcare and biotech companies. He also spent time on "Wall Street" as a junior sell-side analyst following healthcare and biotech companies. Mr. Gill earned a Bachelor of Science degree in biology and chemistry from West Chester University.

James Gilligan, Ph.D., MSIB, vice president for product development, Unigene Laboratories, Inc.

Dr. James Gilligan has been employed by Unigene since 1981 and has served as vice president of product development since April 1999. From February 1995 to March 1999, he served as director of product development. Dr. Gilligan holds a Ph.D. in pharmacology from the University of Connecticut and a Masters of International Business from Seton Hall University.

Glenn Gormley, M.D., Ph.D., president and CEO, Gemin X Pharmaceuticals, Inc.

Dr. Glenn Gormley is president and CEO of Gemin X Pharmaceuticals. He was formerly global head of clinical development and medical affairs at Novartis. In this capacity he served as a senior member of the Novartis development management team and general medicines executive committee. Prior to joining Novartis, Dr. Gormley served as chief medical officer for AstraZeneca and a member of the senior management teams. While at AstraZeneca Dr. Gormley continued as a member of the Adjunct Clinical Faculty at New York University and served as a Trustee of the University of Delaware. Prior to joining AstraZeneca, Dr. Gormley spent 12 years at Merck in Clinical Development. Dr. Gormley received his M.D. and Ph.D. in Chemistry from the University of Chicago and received board certifications in Pediatrics from UCLA and Pediatric Endocrinology from New York University.

Troy Harmon, vice president, business development, Eurand

Troy Harmon is currently vice president, business development for Eurand. Mr. Harmon is responsible for Eurand's business development, licensing, and commercial efforts in North America. Prior to Eurand, Mr. Harmon was director, business development at Delsys Pharmaceutical, director, business and product development at FEI Technologies, and as senior scientist at Summit Technology.

Mr. Harmon received his BS degree from the University of Kentucky, where he received the University's first prize for undergraduate academic research. Mr. Harmon also holds a MS degree in Physical Chemistry from Cornell University, and a MBA from Villanova University.

Robert Hayes, Ph.D., venture leader, Centyrex, Johnson & Johnson Ventures

Robert Hayes received his Ph.D. degree from Imperial College of Science in London for work on protein structure and RNA-protein interactions, and he did postdoctoral work at Imperial and also at the University of California in Berkeley. In 2004, Mr. Hayes joined Centocor R&D as senior director of protein engineering, where his group focused on the development of an alternative scaffold as a biotherapeutic platform. Early success of the scaffold led to the foundation of Centyrex, an Internal Venture co-funded by Centocor and Johnson & Johnson Development Corporation. The venture officially began on January 2008, with Mr. Hayes as the venture leader.

Janice Hogan, managing partner, Hogan & Hartson LLP

Ms. Hogan is the managing partner of the Philadelphia office of Hogan & Hartson LLP and co-director of the firm's FDA practice group. Her practice focuses primarily on the representation of medical device, pharmaceutical, and biological product manufacturers before the FDA. She is a frequent lecturer at FDA symposia and has been named by Who's Who Legal to the International Who's Who of Life Science Lawyers for 2008. Ms. Hogan received dual B.S. degrees from M.I.T. in mechanical engineering and literature, and her law degree from the Georgetown University Law Center, magna cum laude.

Tamar Howson, corporate and business development

Tamar Howson served most recently as executive vice president of corporate business development at Lexicon Pharmaceuticals. Between 2001 and 2006, she

served as senior vice president of corporate and business development and member of the executive committee at Bristol-Myers Squibb, managing the execution of licensing agreements and research collaborations. She is a member of the board of Bioline Rx, and BioNJ. Ms. Howson received her B.S. from Technion in Israel, M.S. from City College of New York and M.B.A. from Columbia University.

Robert Hrubiec, Ph.D., J.D., vice president, intellectual property, Cephalon, Inc.

Robert Hrubiec, Ph.D, J.D. is vice president, intellectual property at Cephalon, Inc., a mid-sized pharmaceutical company located in Frazer, Pennsylvania, where he is responsible for leading the worldwide management and direction of the company's IP department. Prior to joining Cephalon in 1999, Dr. Hrubiec was an intellectual property attorney with GlaxoSmithKline. He has broad experience in pharmaceutical intellectual property, transactional matters, due diligence, regulatory matters, litigation, trademarks, copyrights and strategic IP evaluation and management.

Dennis Jackman, senior vice president, public affairs, CSL Behring

Dennis Jackman is responsible for strategies to optimize stakeholder impact on CSL Behring's ability to provide lifesaving therapies worldwide. He oversees policy development, government and industry affairs, internal and external communications, ally/coalition development and company associates. His areas of expertise include reimbursement, regulatory policy and international trade. He has held senior public affairs positions in the pharmaceutical and biotechnology industries since 1989. Before this he was senior legislative aide to U.S. Senator Arlen Specter of Pennsylvania. Mr. Jackman holds a master's degree in business administration from Cornell University Johnson School of Management. He received his bachelor's degree in sociology from Pennsylvania State University.

John H. Johnson, CEO, ImClone Systems Incorporated

John H. Johnson has 25 years of executive and operational management experience in the biopharmaceutical and healthcare industries. Prior to joining ImClone as its CEO in August 2007, Mr. Johnson served as company group chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit. In this executive role, he was responsible for the Johnson & Johnson biotechnology, immunology and oncology commercial businesses, including Centocor, Ortho Biotech Products and the Worldwide Strategic Marketing Group. Prior to joining Johnson & Johnson in 1988, Mr. Johnson was with Pfizer. Mr. Johnson received a B.S. degree from East Stroudsburg University in Pennsylvania.

Perry Karsen, senior vice president, business development, Celgene Corporation

Perry Karsen is senior vice president, business development at Celgene Corporation, responsible for business development, licensing and strategic collaborations. Previously, he was senior vice president, business development, Human Genome Sciences. Mr. Karsen's career began at Abbott Laboratories. He was director, business development and representative director, Japan at Genentech. At Bristol-Myers Squibb, he was vice president, strategic business analysis and development, vice president, corporate development, and senior vice president, marketing at Zimmer, Inc. He was also a general partner at Pequot Ventures, handling early- and late-stage biotechnology and medical device investments. Mr. Karsen has a Masters of Management, Northwestern University's Kellogg Graduate School of Management, Masters in Teaching of Biology, Duke University, and BS in Biological Sciences, University of Illinois, Urbana.

Richard Kender, senior vice president, business development & corporate licensing, Merck & Co., Inc.

At Merck, Mr. Kender is responsible for business development, corporate licensing, human health business development, U.S.H.H. business development, MVD business development, financial evaluation and analysis and JV financial services. He serves on the Finance Senior Leadership Team and Merck Capital Ventures Investment Committee. Mr. Kender joined Merck in 1978, holding a variety of positions in finance. In 1994 he joined corporate development and was promoted in 1996 to vice president, corporate development. His responsibilities expanded to include corporate licensing and worldwide business development in 2002. Mr. Kender earned a BS in Accounting from Villanova and a MBA from Fairleigh Dickinson University. He serves on ev3 Inc. (in Plymouth, MN) and BioNJ boards.

Joachim Kohn, Ph.D., professor of Chemistry & Chemical Biology, Rutgers, the State University of New Jersey

Professor Joachim Kohn is the Board of Governors Professor of Chemistry and Chemical Biology at Rutgers University, and an adjunct associate professor of Orthopedics at the New Jersey Medical School. He has served as director of the New Jersey Center for Biomaterials since its establishment in 1997. He is a fellow of the American Institute for Medical and Biological Engineering, and the International Union of Societies for Biomaterials Science and Engineering. He is the principal investigator of several leading federally-funded R&D programs. His research interests focus on developing new biomaterials. He pioneered the use of combinatorial and computational methods for the optimization of biomaterials for specific medical applications.

Ray Krauss, CEO, Glucolight Corporation

Mr. Krauss has 26 years experience in the medical device industry, including management assignments in ophthalmology, diagnostic ultrasound, neurology, cardiology and endocrinology. He has previously held executive positions with Johnson & Johnson (10 years) and was chief operating officer of Summit Technology (4 years). Mr. Krauss is currently CEO & co-founder of GlucoLight; a medical device company developing a non-invasive, continuous glucose monitor for both hospital and consumer applications. Mr. Krauss also serves on the Board of Directors of Pennsylvania Bio. He holds a BSEE from Lehigh University, MSEE and MBA degrees from Case Western Reserve University.

Barry Kreiswirth, Ph.D. director, PHRI TB Center, University of Medicine and Dentistry of New Jersey

Dr. Barry Kreiswirth joined PHRI as a graduate student in 1978, working on the molecular biology of Staphylococcus aureus and after 25 years he has become the director of the PHRI Tuberculosis Center. His doctoral thesis was on the cloning and genetic characterization of the toxic shock syndrome toxin-1. He remained as a post-doc and research assistant, working on the molecular epidemiology of TSS and methicillin resistant S. aureus (MRSA) and developing genotyping tools to sub-speciate S. aureus strains. In response to the 1992 New York City tuberculosis outbreaks, the PHRI TB Center was established under his direction as a genotyping laboratory studying the molecular epidemiology of tuberculosis.

Karen LaRochelle, executive director, business development, Bristol-Myers Squibb Company

Karen LaRochelle is an executive director of business development at Bristol-Myers Squibb focusing on M&A and pharmaceutical business collaborations. Since 2000 she has worked extensively in support of BMS' worldwide commercial and R&D operations including execution of several oncology and cardiovascular collaborations. Ms. LaRochelle joined BMS in 1993, holding successive positions involving financial and business evaluation. Prior to BMS, she was a management consultant with Accenture.

Ms. LaRochelle earned her B.S. in Industrial Engineering from Lehigh University and an MBA from Columbia University. She currently serves on the Business Development Board of BioNJ. She resides near Princeton, NJ with her husband and three sons.

Frank LaSaracina, founder, SouthPoint Associates LLC

Frank LaSaracina is founder of SouthPoint Associates LLC, a consultancy focused on biopharma companies. With more than 30 years of relevant business experience, including nearly 25 in biopharma, he assists clients with business development, expansion, and financing.

Prior to SouthPoint Associates, he was managing director of Speedel Pharmaceuticals, Inc, the US subsidiary of Speedel Holding, a Swiss biopharma acquired by Novartis for CHF 1.0 billion in October 2008.

Mr. LaSaracina has extensive international life sciences experience in business development, licensing, strategic planning, and corporate development, holding numerous management positions at Ciba Geigy and Novartis for 20 years. He also serves as treasurer of BioNJ.

Len Lavenda, vice president, communications, sanofi pasteur US

Len Lavenda is vice president, communications for sanofi pasteur US. He is responsible for the development of all internal and external communication initiatives including employee communications, product publicity, corporate communications, media relations and community relations. He also manages the company's philanthropy program in the US. Mr. Lavenda has a bachelor's degree in Engineering from Rensselaer Polytechnic Institute in Troy, New York. Prior to joining sanofi pasteur in 1996, he worked in a variety of communications positions, including corporate communications, marketing communications, financial communications, employee communications and community relations.

King Lee, Ph.D., R.A.C., vice president, regulatory and clinical affairs, Cornerstone Pharmaceuticals, Inc.

With more than 20 years experience in the life sciences, King Lee, Ph.D., R.A.C. is the vice president of regulatory and clinical affairs for Cornerstone Pharmaceuticals, Inc., a company developing novel anti-cancer agents such as Altered Energy Metabolism-Directed (AEMD) compounds that affect tumor-specific pyruvate dehydrogenase complex (PDC). He earned his Ph.D. in Pharmacology from the College of Medicine of the University of Kentucky (1983) and was certified by the Regulatory Affairs Professionals Board in 1994.

Greg Licholai, M.D., vice president, medical affairs, Amicus Therapeutics

Greg Licholai, M.D. is currently the vice president for medical affairs and member of the executive team at Amicus Therapeutics. Previously, he was at the venture capital firm Domain Associates and had been the director of ventures and business development for Medtronic Neurological. Dr. Licholai trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals and did research at the National Institutes of Health and Rockefeller University. He studied at Boston College and Columbia University, received an M.D. from Yale Medical School and an MBA from Harvard Business School.

Nils Lonberg, Ph.D., senior vice president & scientific director, Medarex, Inc.

Nils Lonberg received his Ph.D. from the Department of Biochemistry and Molecular Biology at Harvard University in 1985. He joined GenPharm International in 1990. At GenPharm, Dr. Lonberg's research group developed a mouse with human antibody genes for the generation of fully human monoclonal antibodies. In 1997 GenPharm became a subsidiary of Medarex, where Dr. Lonberg is now senior vice president & scientific director.

Doug Long, vice president of industry relations, IMS HEALTH

Doug Long is vice president of industry relations at IMS HEALTH, the world's largest pharmaceutical information company. IMS HEALTH offers services to the pharmaceutical industry in over 101 countries around the globe. He has been with IMS HEALTH since 1989. His fundamental task is to help secure data for all existing and new databases supported by IMS HEALTH, manage supplier, manufacturer & association relationships, and develop information for data partners. Prior to IMS HEALTH, he was at Nielsen Market Research for sixteen years in various sales and marketing capacities. Mr. Long received a BA degree from DePauw University in Greencastle, IN, and an MBA in Management from Fairleigh Dickinson University.

Julia Lukas, director, regulatory affairs compliance, sanofi pasteur

Julia Lukas started her professional career with the FDA, serving 12 years at The Center for Biologics Evaluation and Research (CBER) as a BLA reviewer and inspector, performing both pre- and post- approval inspections. Her areas of focus were biotechnology products, vaccines, and blood screening products. After leaving FDA in 2001, Ms. Lukas worked as a consultant with PharmaNet and The Biologics Consulting Group. Ms. Lukas' consulting practice focused on regulatory affairs, GMP compliance, and helping companies prepare for pre- approval inspections. Ms. Lukas joined sanofi pasteur in 2004. Based at the Pennsylvania headquarters, she heads up the US Regulatory Affairs Compliance staff.

Annaire Lyles, Ph.D., senior vice president, head of business development, Genmab, Inc.

Dr. Annarie Lyles joined Genmab in 2005. She has been engaged in biology-related businesses for nearly two decades, including a prior business development post with Medarex, Inc. She speaks frequently at licensing-related conferences and has served on professional committees for organizations including BIO, BioNJ, and the New Jersey Economic Development Authority. Dr. Lyles earned undergraduate and graduate biology degrees from Yale and Princeton Universities.

John Maki, president & CEO, Vicus Therapeutics

John Maki is president and CEO of Vicus Therapeutics, a privately-held biopharmaceutical company focused on oncology supportive care drug products. Previously he was managing director of Technology Directors, Inc. from 2001-2005 and 1997-1999; managing director of the Audax Group from 1999-2001; a principal at Bain Capital from 1988-1997; and a consultant at Bain & Company from 1983-1988. Mr. Maki has more than 20 years of industry experience and has been a founding investor and/or board member of eleven life science companies. In addition, three of his portfolio companies had successful IPOs and grew to a combined market capitalization exceeding $1.4 billion. He serves on the boards of 3DMatrix, Addition Technology, and BioNJ. He holds an AB from Harvard.

Jeffrey Marx, Ph.D., vice president of corporate development, Orthovita, Inc.

Jeffrey Marx completed his Ph.D. in ceramic engineering at the University of Missouri Rolla in 1995. Dr. Marx led a biomaterials program focused on ceramic based bone substitutes for Phillips Plastics corp in Wisconsin leading to multiple patents and one commercial product. Dr.

Marx joined Orthovita in August 1999 as director of product development to lead the commercialization of the Vitoss® scaffold. He has held various roles during his tenure at Orthovita including marketing, sales management, and medical education. Currently, as vice president of corporate development, he is responsible for strategy and business development.

Paul Medeiros, principal, The BioTransactions Group

Paul Medeiros is a principal with The BioTransactions Group, a consulting firm offering business development, licensing and transaction services to emerging biotech, pharmaceutical and medical device companies. He is also a co-founder of SomTherapeutics Inc, a start-up company focusing on novel somatastain analogues for treating certain endocrine related diseases. Previously, he was vice president, global licensing & strategic alliances at Schering-Plough. He received his M.B.A. from Columbia University Graduate School of Business and an A.B. from Brown University.

Ross Murdoch, Ph.D., senior vice president, emerging business unit, Shire Pharmaceuticals

Dr. Ross Murdoch has 20 years experience in the international pharmaceutical industry and is presently the senior vice president of emerging business at Shire Pharmaceuticals. Prior to joining Shire, Dr. Murdoch has held positions including the president/COO of Prana Biotechnology (NASDAQ listed); CEO/CSO of Kinacia Biotechnology; head of global project management & US clinical operations for AstraZeneca and, head of Australian R&D and director in global project management at SmithKline Beecham. Dr. Murdoch has a B.Sc honors degree & postgraduate Health Economics degree (Monash University), a Ph.D. in Pharmacology (Melbourne University), and is a graduate of the Australian Institute of Company Directors.

Brian Murphy, partner, NewSpring Capital

Brian Murphy is a partner of NewSpring Capital, with more than 20 years of private equity, corporate management and development experience, focused primarily in health care services. His background is in business strategy, investment structuring, organizational growth, and negotiation of mergers and acquisitions. He is currently on the Boards of RedPath Integrated Pathology, Habit Management, Cybershift, TMG Health, Othera Pharmaceuticals, RecoverCare, SongBird Hearing, Precyse Solutions and the Foundation Board of SUNY Cortland.

P. Sherrill Neff, managing partner, Quaker BioVentures

Mr. Neff is a founding partner of Quaker BioVentures. He was previously chairman of the Greater Philadelphia Venture Group and previously president of the Pennsylvania Biotechnology Association. He sits on the following boards of directors: Amicus Therapeutics, Biolex Therapeutics, Neuronetics, Optherion, Regado Biosciences, Resource Capital Corporation, University City Science Center, the Biotechnology Institute, and the Policy Board of WXPN at the University of Pennsylvania. Prior to forming Quaker BioVentures, he was president, chief operating officer, and a director of Neose Technologies, Inc., a publicly-traded life sciences company. Previously, Mr. Neff was senior vice president, corporate development at U.S. Healthcare, Inc., a leading publicly-traded health maintenance organization. Mr. Neff was formerly a managing director in the investment banking division of Alex Brown & Sons, and formerly an attorney at Morgan, Lewis & Bockius. Mr. Neff is a graduate of Wesleyan University and the University of Michigan Law School.

Steven Nichtberger, M.D., president & CEO, Tengion Inc.

Dr. Nichtberger, a 15-year veteran of the pharmaceutical and biotechnology industries, co-founded Tengion in 2004. Previously, Dr. Nichtberger was a member of the Merck senior management team, where his leadership roles included: global marketing for all Merck brands; P&L responsibility for a $3.5 billion US product portfolio; and the new product planning function. Formerly, Dr. Nichtberger founded a profitable company that licenses intellectual property in the field of paperless couponing. He holds a BA in Biology from University of Pennsylvania, a BS in Economics from the Wharton School, and an M.D. from the School of Medicine and Biosciences, SUNY Buffalo.

Nicholas Nicolaides, Ph.D., president & CEO, Morphotek, Inc.

Nicholas Nicolaides Ph.D. is a co-founder of Morphotek. Dr. Nicolaides co-invented morphogenics, a whole genome evolution technology that became the basis of Morphotek. He recently received the 2007 Ernst & Young Entrepreneur of the Year® award for his innovations and contributions to the life science industry in the Greater Philadelphia Region.

Prior to joining Morphotek, Dr. Nicolaides was director of research at the Magainin Institute of Molecular Medicine, a division of Magainin Pharmaceuticals Inc. Dr. Nicolaides' scientific background is in human molecular genetics, where he has studied and authored many scientific papers on the molecular and genetic basis of cancer and respiratory diseases.

Dr. Nicolaides received his Ph.D. in genetics at Thomas Jefferson University, Philadelphia, PA and continued his post-doctoral training at Johns Hopkins University, Baltimore, MD.

Shawn Patrick O'Brien, president & CEO, Profectus BioSciences Inc.

A 26 year biotech and big pharma executive leader with experience building highly successful global enterprises, Mr. O'Brien has extensive global experience in business development, marketing, selling, licensing, researching and developing both small and large molecules.

Mr. O'Brien joined Profectus in January of 2008 as president and CEO. Prior to joining Profectus, he was the president and CEO of Solstice Neurosciences Inc. for 3 years, based in Malvern, PA. Previously, he held executive positions with AstraZeneca Pharmaceuticals, most recently as vice president of commercial operations for emerging brands. Previously, he led AstraZeneca's business operations for the respiratory and oncology therapeutic areas, each having in excess of $1 billion in sales.

Tom Petzinger, CEO, LaunchCyte LLC

Tom Petzinger is executive vice president of Knopp Neurosciences Inc. and CEO of LaunchCyte LLC, a Pittsburgh-based biotechnology development company. Previously he spent 22 years as a reporter, editor, and columnist with The Wall Street Journal, where he also served as Washington economics editor, millennium editor, and bureau chief. He is the author of three business books, two selected as "Notable Books of the Year" by The New York Times.

Mr. Petzinger also serves as chairman of Crystalplex, treasurer of Reaction Biology, chairman of Immunetrics, and director of Celsense Inc. He serves on the board of Pennsylvania Bio and holds a journalism degree from Northwestern.

Peter Pfreudschuh, CFO, CircuLite

Peter Pfreundschuh is the CFO at CircuLite. Prior to this, he was executive director of business development and licensing at AstraZeneca. At AstraZeneca, his team played an intricate role in leading business development activities in support of AZ's strategy in North America. His team's responsibilites included engagement in due diligence activities, commercial and financial/business analysis, and deal negotiation and execution activities. His personal experiences include a broad base of financial, research and development, and commercial experiences both within and outside of the pharmaceutical industry.

Mr. Pfreundschuh holds a BS in Accounting from Rutgers University, a MBA from Rider University in Finance, an Executive Degree in Strategic Marketing from Northwestern University (Kellogg School of Management), and a CPA from the State of New Jersey.

David Pompliano, Ph.D., vice president and head of antimicrobials discovery and early development strategy, Merck Research Laboratories

David Pompliano is vice president and head of antimicrobials discovery and early development strategy at Merck Research Laboratories. After receiving honors in chemistry from the University of Virginia and a Ph.D. in bioorganic chemistry from Stanford University with John Frost, he was an NIH postdoctoral fellow in enzymology and molecular biology at Harvard University with Jeremy Knowles. Before joining Merck, he was head of biology at GlaxoSmithKline for infectious diseases (including diseases of the developing world), cancer, and musculoskeletal diseases. He has published more than 50 research papers in antimicrobials and cancer, has given more than 25 invited lectures internationally, and holds three patents.

Tibby Posillico, Ph.D., president & CEO, Elusys Therapeutics, Inc.

Dr. Tibby Posillico joined Elusys in 2002, serving as vice president of business development and senior vice president of operations before being promoted to president & CEO in 2005. Dr. Posillico has 20 years of experience in the biopharmaceutical industry and has held senior level positions in business development, marketing, and management at Physiome Sciences, Apoptogen, Inc., Genzyme Corporation, and Damon Biotech. Dr. Posillico received a B.A. from the State University of New York at Potsdam and a Ph.D. from Duke University. She currently serves on the board of the BioNJ and the Morris Area Girl Scout Council.

Steven Projan, Ph.D., vice president and global head of infectious diseases, Novartis Institutes for BioMedical Research

Steven Projan attended MIT, receiving an S.B. degree in the Life Sciences and Nutrition & Food Science and a Ph.D. from Columbia University. Dr. Projan then became a postdoctoral fellow, and later an associate, at the Public Health Research Institute. In 1987, he became a senior scientist and then group leader at Applied Microbiology, Inc. At the end of 1993, he moved to Lederle Laboratories as a group leader in anti-infectives research, which became part of Wyeth Research. Dr. Projan held positions of increasing responsibility at Wyeth from 1997-2008, including associate director, bacterial genetics; director, antibacterial research; assistant vice president; and then vice president of the newly created Dept. of Biological Technologies. In 2008, Dr. Projan became vice president and global head of infectious diseases at the Novartis Institutes for Biomedical Research.

Navaneetha Rao, Sc.D., vice president clinical research and development, Vicus Therapeutics

Navaneetha Rao is vice president clinical research and development of Vicus Therapeutics, a privately-held biopharmaceutical company focused on oncology supportive care drug products. He was previously assistant vice president, clinical research and development, Reliance Life Sciences (India) and head, Reliance Clinical Research Services, 2004-2006; associate director, clinical development, Cato Research Limited, 1998-2004; and Post Doctoral Research Fellow, Brigham and Women's Hospital, Harvard Medical School, 1994-1998. He holds an Sc.D., from Harvard, M.S. from Virgina Tech and B.Sc. from NDRI, India.

H. Joseph Reiser, Ph.D., president & CEO, CureDM Inc.

H. Joseph Reiser, is the president & CEO of CureDM Inc. Prior to this, he was president and CEO of Locus Pharmaceuticals, Inc., a clinical-stage biotech company. Previously, Dr. Reiser served as president, CEO, and member of the Board of CYTOGEN Corporation, a product oriented Oncology Company. Dr. Reiser was also corporate vice president and general manager, pharmaceuticals and a member of the Board of Berlex Laboratories, Inc., the U.S. subsidiary of Schering AG. During his 17 year tenure, Dr. Reiser also served as the first president of Schering Berlin's Venture Corporation. Dr. Reiser served on the boards of various biotech companies and as chairman of BioNJ from 2001-2002. Dr. Reiser received his Ph.D. in Physiology from Indiana University School of Medicine.

William Roberts, vice president of corporate communications, ViroPharma Incorporated

William Roberts, vice president of corporate communications for ViroPharma Incorporated, has 12 years of broad communications experience, including investor and public relations, internal communications, and patient and professional advocacy. He joined ViroPharma after 12 years with MedImmune Inc., culminating in his tenure as director, investor relations. He also worked in MedImmune vaccine discovery, targeting HIV, Lyme disease and cancer. He began his professional career as a staff scientist in genetics for the University of Virginia. Mr. Roberts holds a master's of business administration from the Keller School of Business and a bachelor's degree in biology from the University of Virginia.

Charles Rowland, Jr., vice president & CFO, ViroPharma Incorporated

Mr. Rowland has more than 25 years of pharmaceutical industry experience. Most recently he was executive vice president and CFO of Endo Pharmaceuticals. Prior to joining Endo, he was senior vice president and CFO of Biovail Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Biovail in 2004, he had served since 2001 as chief operating and financial officer for Breakaway Technologies, a management consulting company. His pharmaceutical industry career includes positions of increasing scope and responsibility at Pharmacia Corp., Novartis Pharmaceuticals Corp, and Bristol-Myers Squibb.

Avijit Roy, Ph.D, director, Five Prime Advisors

Dr. Roy came to Five Prime Advisors from Immunicon Corporation, where as senior director of corporate development he led licensing, strategic alliance, and corporate acquisitions and had a key role in its 2004 IPO. Previously, he was associate director of life science licensing at the University of Pennsylvania. Earlier, working for both technology focused and fully integrated companies in biopharmaceuticals and diagnostics, he negotiated licensing agreements and strategic alliances with companies such as Pfizer, AstraZeneca, GlaxoSmithKline, and Genzyme.

Will Sargent, vice president of investor relations & corporate communications, Auxilium Pharmaceuticals, Inc.

Will Sargent is currently the vice president of investor relations and corporate communications at Auxilium Pharmaceuticals. For the 3 years prior to Auxilium, he was a biotechnology equity research analyst at Banc of America Securities. Preceding equity research, he was industry background includes pharmaceutical clinical research, as well as sales, marketing and alliance experience with Amgen and Immunex.

Glenn Sblendorio CFO & executive vice president, The Medicines Company

Glenn Sblendorio has been CFO and executive vice president of The Medicines Company since March 2006. Previously he was executive vice president and CFO of Eyetech Pharmaceuticals, Inc. which was acquired in November 2005. From July 2000 to February 2002, he served as senior vice president, business development for Eyetech. From 1998 to July 2000, he was CEO and managing director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., in a variety of senior financial positions. He received his BBA in accounting from Pace University and his MBA in finance from Fairleigh Dickinson University.

Christian Schade, senior vice president, finance & administration and CFO, Medarex, Inc.

Christian Schade, senior vice president, finance and administration, and CFO, joined Medarex in October 2000. Previously Mr. Schade was a managing director of Merrill Lynch & Co. Mr. Schade was employed by Merrill Lynch from March 1992 until October 2000, and was involved in Merrill Lynch's international capital markets and corporate funding groups. Mr. Schade is a graduate of Princeton University and received an M.BA. from the Wharton School of the University of Pennsylvania.

Zev Scherl, general partner, NewSpring Capital

Mr. Scherl has significant principal investing, corporate management and finance experience in life science and health care. Before NewSpring Capital, he originated and executed investments in emerging life sciences and health care companies for Pequot Ventures. Previously, he was at Behrman Capital. Before entering private equity in 1997, he was at Value Health, Merck & Co., and Lehman Brothers. He is a board member at AppTec Laboratory Services, Scandius BioMedical, Inc., EKR Therapeutics, Nitric BioTherapeutics, Core Essence Orthopaedics and Immune Control, Inc. He received a B.A. from Duke University and an M.B.A. from Harvard.

Barbara Schilberg, managing director & CEO, BioAdvance

Ms. Schilberg has more than 20 years experience in life sciences. Under her leadership as CEO, BioAdvance has invested $14 million in 25 seed-stage companies and 13 pre-seed projects focusing in areas including Alzheimer's disease, cancer, diabetes, obesity and infectious diseases. The portfolio companies have gone on to raise more than $900 million in additional funding and six have been sold.

Ms. Schilberg's industry experience includes senior management positions at Cephalon, Incara Pharmaceuticals, Advanced Medicine (now Theravance) and Locus Discovery, Inc. Before joining the industry, Ms Schilberg represented biopharmaceutical companies and universities as a partner with Morgan, Lewis & Bockius. She received a J.D. from the University of Virginia.

Chris Schnittker, CPA, vice president & CFO, VioQuest Pharmaceuticals, Inc.

Christopher Schnittker, CPA, currently serves as vice president and CFO of VioQuest Pharmaceuticals, a publicly-traded biotechnology company based in Basking Ridge, NJ. Prior to that, Mr. Schnittker served as the senior vice president and CFO for Micromet Inc., Cytogen Corporation, and Genaera Corporation, all NASDAQ-traded biotechnology companies based around the Philadelphia area. Mr. Schnittker has also held financial management positions at GSI Commerce, Rhône-Poulenc Rorer (now part of sanofi-aventis), and PricewaterhouseCoopers. He received his BA in economics and business from Lafayette College and is a certified public accountant licensed in the State of New Jersey.

Gary Sender, CFO and vice president of finance & administration, Tengion Inc.

Gary Sender came to Tengion as its CFO from ARAMARK where he was vice president, investor relations. Prior to ARAMARK, Mr. Sender was employed at Merck & Co., Inc. serving as vice president, controller for Merck's U.S. pharmaceuticals business. During his 15-year career with Merck he also served as assistant treasurer, executive director of financial evaluation and analysis, executive director, joint venture financial management, director of investor relations and manager, foreign exchange. Prior to his career at Merck, Mr. Sender held positions at AT&T and RCA. Mr. Sender earned his bachelor's degree from Boston University, and received his master's degree in Industrial Administration (MBA) from Carnegie-Mellon University.

Scott Siegel, Ph.D., vice president of corporate development, RedPoint Bio Corporation

Dr. Scott Siegel has 23 years experience in business and R&D leadership for biotechnology and pharmaceutical companies. He is currently vice president, corporate development for Redpoint Bio, a public biotechnology company. Previous roles include worldwide strategic marketing and new business development for Johnson & Johnson, and R&D for Phytera, Inc., Centocor, Inc. and Becton Dickinson. He earned his Ph.D. in biochemistry from SUNY Downstate Medical, completed postdoctoral studies at Yale University and was adjunct faculty at the University of Pennsylvania. He is co-inventor of Remicade®, a drug used to treat autoimmune disorders, author of more than 30 publications and holds more than 30 patents.

Philip Smith, partner, SR One

Philip Smith is a partner with SR One focused on biotechnology/drug delivery. He is currently on the Boards of Cydex, Onyvax, OctoPlus, Trinity Biosystems and Scynexis (observer). Mr. Smith is a member of the CVG Advisory Board of the NVCA and is on the Board of the MAC Alliance. Prior to SR One, he headed up a transnational group responsible for identification and recommendation of internal development of drug delivery technologies for product development at SB/GSK (1985-2002).

Mel Sorensen, M.D., president and CEO, Ascenta Therapeutics, Inc.

Mel Sorensen, M.D., is president and CEO of Ascenta Therapeutics (Malvern, PA), a cancer R&D company with a portfolio of apoptosis triggering agents. He is also chairman of Ascenta's wholly-owned subsidiary in Shanghai. Dr. Sorensen is a medical oncologist who, before joining Ascenta in 2004, had spent approximately seven years each in patient care (St. Louis, Mayo Clinic), the National Cancer Institute, and in leadership positions in clinical cancer research in the pharmaceutical industry (Bayer and GSK). Under his leadership, Ascenta secured $94M in financing and advanced its lead program from preclinical development into multiple randomized trials.

Jack Stover, former CEO, Antares Pharma Inc.

Jack Stover joined Antares Pharma as president and COO in July 2004 and was appointed CEO and a member of the Board of Directors in September 2004. Prior to joining Antares Pharma, he was executive vice president and CFO of Sicor, Inc., a public injectable pharmaceutical company acquired by Teva Pharmaceuticals. Prior to Sicor, Mr. Stover was executive vice president for a proprietary women's drug company, Gynetics, Inc., and before Gynetics, he was senior vice president for B. Braun Medical, Inc., a private global medical device and product company. For more than five years, Mr. Stover was a partner with PricewaterhouseCoopers.

Chris Szustkiewicz, Ph.D., MBA, vice president of regulatory affairs & compliance, Lux Biosciences

With 15 years of senior management experience in the life sciences, Christopher Szustkiewicz is currently vice president of regulatory affairs and compliance at Lux Biosciences, Inc. Previously, he was senior director regulatory affairs at GPC Biotech, responsible for NDA submission for satraplatin. Before GPC Biotech, he was vice president, regulatory affairs and strategic development at Target Health and was vice president project planning and regulatory affairs at Pharmacologics. Until 1998, he was vice president of MDS China, directing clinical drug development programs in Oncology, and Infectious Disease. He holds an Executive MBA at Lake Erie College and a Ph.D. in Pharmacogenetics at West Virginia University.

Kevin Taylor, vice president, business development, Adolor Corporation

Kevin Taylor has been vice president, business development for Adolor Corporation since July 2003. Mr. Taylor leads Adolor's partnering activities and last December concluded a worldwide licensing and development collaboration with Pfizer involving Adolor's Delta Opioid Receptor Agonist program. Previously, Mr. Taylor was vice president, business development of Codexis, Inc., a privately-held biosciences company, where he concluded multiple transactions and built a business development team with strategic hires in Europe and the US. For the last 19 years, Mr. Taylor has worked in the life sciences industry, where he held senior positions in business development and commercial operations at companies including Elan Corporation, Zeneca, Inc., and Cambrex Corporation. Mr. Taylor earned a M.S. in Management from the Wharton School of Business and a B.S. in Polymer Science and Chemistry from The Pennsylvania State University.

Paul Thomas, former chairman, president & CEO, LifeCell Corporation

Paul Thomas served as chairman of the Board, president and CEO of LifeCell Corporation from 1998 through the successful acquisition of LifeCell by KCI. Prior to joining LifeCell in 1998, he was president of the Pharmaceutical Products Division of Ohmeda Inc. Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business, completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science and received his B.S. degree in Chemistry from St. Michael's College in Vermont. He serves as a director of Innovative Spinal Technologies, Inc. and Orthovita, Inc.

Steve Tullman, president & CEO, Ception Therapeutics, Inc.

Mr. Tullman is co-founder, president and CEO of Ception Therapeutics, a private biopharmaceutical company headquartered in Malvern, PA. Prior to Ception, he co-founded Trigenesis Therapeutics which was acquired in 2004.

His career began at SmithKline Beecham (now GSK). He held a number of key positions including the head of GSK's global commercial strategy for musculoskeletal, inflammation and dermatology, strategic director for respiratory new product development, international marketing director for the Philippines, associate director for anti-infective products and global brand director for Bactroban®.

Mr. Tullman is a co-founder and director of PreSun® Co. and a member of the Euromed Board.

Anne VanLent, president, AMV Advisors

Anne VanLent is president of AMV Advisors, providing strategic planning and financial services to emerging growth life sciences companies.

She served as executive vice president and CFO of Barrier Therapeutics from 2002 to May 2008, where she managed four public and two private financings and was responsible for finance and accounting, public relations and investor relations, human resources, and information technology.

Ms. VanLent has more than 25 years of senior management experience with both private and public emerging growth companies in healthcare and technology. Before Barrier, she was executive vice president, portfolio management for Sarnoff Corporation. She serves as a director and audit chair for Integra Life Sciences Holdings Corp and Penwest Pharmaceuticals.

Bruce Wagman, RN, MBA, RAC, vice president, regulatory affairs and quality assurance, clinical development services, Covance Inc.

As regulatory affairs officer for Covance Late Stage Development Services, Bruce Wagman assists Covance clients with the development of their regulatory strategy and submissions. In addition to his consulting role with internal and external clients, he provides the leadership and strategic direction for Covance Incorporated worldwide regulatory affairs and regulatory compliance operations. As the general manager, Interactive Voice Response System (IVRS), he managed the budget, client and vendor contract negotiations and personnel.

Tim Wert, senior director, provider & payor services, ImClone Systems Incorporated

Since early 2007, Tim Wert has held the position of senior director, provider & payor services with ImClone Systems Incorporated. In this role, he heads up the team that assesses reimbursement policy and patient access trends relating to Erbitux®, which is ImClone's monoclonal antibody indicated for use in CRC and H/N cancer.

Mr. Wert's career encompasses more than 26 years in the pharma/biotech industry, with his main focus being in Oncology. He has served in various capacities within sales, marketing, reimbursement policy, distribution, advocacy and business development, thus enabling him to develop a broad and proficient perspective of the business.

Michael Williams, Ph.D., D.Sc., vice president, discovery research, Cephalon, Inc.

Michael Williams, Ph.D., D.Sc. is vice president, discovery research at Cephalon, Inc., in West Chester, Pennsylvania and has worked for 32 years in the US-based pharmaceutical industry. After retiring from Abbott Laboratories in 2000 as divisional vice president for neurological and urological research, he consulted for biotech companies in the US and Europe and was vice president of drug discovery at Molecumetics in Seattle from 2001-2002, joining Cephalon, Inc. in 2003. He is an adjunct professor of Molecular Pharmacology and Biological Chemistry at the Feinberg School of Medicine, Northwestern University, Chicago and of Pharmacology and Physiology at Drexel University School of Medicine in Philadelphia.

Zhenping Zhu, M.D., Ph.D., vice president of research, ImClone Systems Incorporated

Dr. Zhenping Zhu joined ImClone Systems Incorporated in 1996, and has been vice president of research since 2005. He oversees ImClone's research programs in pipeline discovery, antibody technology/engineering and immunology. He is a member of ImClone's Research and Development Review Committee and Research Management Committee. He received his M.D. from Jiangxi Medical College, MSc in Pharmacology from Chinese Academy of Medical Sciences and Peking Union Medical College, Ph.D. in Immunology and Pathology from Dalhousie University, and performed postdoctoral work in antibody engineering at Genentech, Inc. Dr. Zhu has been working in the areas of antibody technologies / applications and cancer biotherapeutics for more than 20 years.